All Posts Tagged With: "GENZ"
(GENZ) Genzyme Corporation Earnings Scorecard
Following the release of first quarter results on April 21, 2010, several analysts covering Genzyme Corporation (GENZ) have lowered their earnings estimates for 2010 and 2011. Genzyme is still suffering from...
(ISIS) Isis Pharmaceuticals Reports Smaller Loss Than Expected
Isis Pharmaceuticals Inc. (ISIS) reported a net loss of 10 cents per share in the first quarter, well below the Zacks Consensus Estimate of a net loss of 17 cents. However, the reported quarter’s loss was...
(GENZ) Genzyme Corporation – Bear of the Day
Genzyme (GENZ) has been under a lot of pressure over the past few quarters following the temporary shutdown of its Allston manufacturing facility due to contamination problems.
While we are pleased...
(ABT) Pharma & Biotech Stock Review – April 2010 – Industry Outlook
The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a...
(BMRN) BioMarin Pharma Announces Good News
BioMarin Pharma Inc. (BMRN) announced recently that its product Firdapse (Amifampridine phosphate) for treating Lambert Eaton Myasthenic Syndrome (LEMS) is commercially available in the European Union.
While...
(GENZ) Genzyme First Quarter Earnings Beat by a Penny
Genzyme Corporation (GENZ) reported first quarter earnings of 24 cents per share, above the Zacks Consensus Estimate of 19 cents but well below the year-ago earnings of 70 cents.
With the company facing...
(GENZ) Genzyme Reports Encouraging Data on Multiple Sclerosis Drug Candidate
Genzyme Corp. (GENZ) recently reported encouraging follow-up phase II results on its multiple sclerosis candidate alemtuzumab at the annual meeting of the American Academy of Neurology. Alemtuzumab is currently...
(ISIS) Isis Pharmaceuticals Signs Deal with GlaxoSmithKline
Isis Pharmaceuticals, Inc. (ISIS) recently inked a major deal with GlaxoSmithKline (GSK) under which Isis ’ antisense drug discovery platform...
(SHPGY) Shire Presents Positive Data on Vpriv
Shire Plc. (SHPGY) recently presented positive phase III data on its Gaucher disease product, Vpriv. The trial was conducted to study the safety of switching patients from Genzyme’s (
(GENZ) Genzyme Corporation Sees FDA Consent Decree Likely
Just when Genzyme Corp. (GENZ) was slowly making some progress in addressing its manufacturing issues, the company announced that the US Food and Drug Administration (FDA) intends to take enforcement action...
(GENZ) Genzyme Likely to See FDA Enforcement Action
Just when Genzyme Corp. (GENZ) was slowly making some progress in addressing its manufacturing issues, the company announced that the US Food and Drug Administration (FDA) intends to take enforcement action...
(ISIS) Isis Pharmaceuticals and Genzyme’s Phase III Drug Data Published
Isis Pharmaceuticals, Inc. (ISIS) and Genzyme Corp. (GENZ) recently announced the publication of phase III data on mipomersen in The Lancet....
(OSIR) Osiris Therapeutics Misses Estimates
Osiris Therapeutics (OSIR) reported a net loss of a cent in the fourth quarter of 2009, well below the Zacks Consensus Estimate of a net income of 23 cents per share. However, net loss in the year ago period...
(ISIS) Isis Pharmaceuticals’ Loss Widens
Isis Pharmaceuticals Inc. (ISIS) reported a net loss of 16 cents per share in the fourth quarter, which was wider than the Zacks Consensus Estimate of a net loss of 11 cents. The company had reported a net...
(BMRN) BioMarin Pharmaceutical’s Earnings Top Analyst Estimates
BioMarin Pharmaceutical Inc. (BMRN) reported fourth-quarter 2009 earnings of 13 cents per share (excluding special items), beating the Zacks Consensus Estimate of break-even earnings. The company had earned...
(ISIS) Isis Pharmaceuticals Falls on Drug Concerns
Shares of Isis Pharmaceuticals Inc. (ISIS) slipped more than 2% despite the company reporting positive results on its lead pipeline candidate, mipomersen. Isis and partner, Genzyme Corp....
(RX) Pharma & Biotech Stock Review – Industry Outlook
The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a...
(GENZ) Genzyme Corporation Gets FDA Action Date for Lumizyme
Genzyme Corp. (GENZ) recently announced that the US Food and Drug Administration (FDA) has assigned an action date for the company’s Biologics License Application for Lumizyme (alglucosidase alfa) for the...
(GENZ) Genzyme Corporation’s Outlook Stabilizing
Genzyme Corp. (GENZ) reports fourth-quarter results on February 17, with the current Zacks Consensus Estimate at 20 cents per share. Recent revisions to the quarterly estimate have been in both directions,...
(KERX) Healthcare Stock Watch: Short List of Booming (and Busting) Companies
by Marc Lichtenfeld, Healthcare Expert
Wednesday, January 20, 2010: Issue...
(ISIS) Isis Pharmaceuticals Expands Pipeline
Isis Pharmaceuticals, Inc. (ISIS) is working on expanding its cardiovascular pipeline. The company recently announced that it has added a new drug, ISIS-APOCIIIRx, to its development pipeline. The candidate...
(GENZ) Genzyme’s Revenues Decline
Genzyme Corp. (GENZ) recently reported preliminary revenues for the fourth quarter and full year ended December 31, 2009. With the company facing manufacturing problems from mid 2009, we were not surprised...
(NKTR) Small-Cap Biotech Stocks: Why This Sector Is Set for a Huge Year
by Marc Lichtenfeld, Healthcare Expert
Wednesday, January 6, 2010: Issue...
(GENZ) Hospira Inks Manufacturing Deal with Genzyme
Genzyme Corp. (GENZ) has entered into a contract manufacturing agreement with Hospira (HSP) for its key drugs Incorporatedluding Cerezyme...
(ISIS) Isis Pharmaceuticals Gains from Teva-OncoGenex Deal
Isis Pharmaceuticals, Inc. (ISIS) stands to benefit from the recently signed agreement between OncoGenex Pharmaceuticals (OGXI) and Teva...
(SHPGY) Shire Seeks U.S. Food and Drug Administration Approval
Shire Plc (SHPGY) recently submitted a biologics license application (BLA) with the U.S. Food and Drug Administration (FDA) for Replagal (agalsidase alfa) meant for treating the genetic disorder Fabry disease.
Replagal...
(PLX) Protalix Biotherapeutics’ Drug Advances
Good news for Protalix Biotherapeutics (PLX) once again! The company completed the submission of its New Drug Application (NDA) with the US Food and Drug Administration (FDA) for taliglucerase alfa, which...
(GENZ) Genzyme’s Announces Positive Campath Oncology Results
Genzyme Corp. (GENZ) recently presented encouraging interim results on its oncology product, Campath, at the annual meeting of the American Society of Hematology (ASH). Results from the randomized phase III...
(GENZ) Genzyme Resumes Cerezyme Shipment
Genzyme Corp. (GENZ) recently reported progress on the resumption of supply of new lots of Cerezyme from its Allston Landing manufacturing facility, which was temporarily shut down due to contamination issues....
(SHPGY) Shire Plc’s Drug Seeks European Medicines Agency Approval
Shire plc (SHPGY) continues to make progress with its Gaucher disease candidate, velaglucerase alfa. The company recently submitted a marketing authorization application (MAA) to the European Medicines Agency...